Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the medication pravastatin will ameliorate renal and cardiovascular disease over a 3-year period in children and young adults with autosomal dominant polycystic kidney disease (ADPKD).


Clinical Trial Description

Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, affecting 1 in 400 to 1000 individuals and accounting for 4% of end-stage renal disease in the United States and 8-10% in Europe. The condition is characterized by progressive development of kidney cysts with kidney enlargement and associated loss of kidney function. High blood pressure and cardiovascular disease are common in patients with ADPKD. Although the condition is often thought to affect primarily adults, it is clear that the disease can be present in the fetus and young children.

This study was designed to determine if treatment with the medicine pravastatin can slow the progression of kidney and heart disease when initiated early in life in patients with ADPKD. The Investigators will assess differences between pravastatin and placebo study groups over the three-year study period with respect to: 1) total kidney volume as assessed by magnetic resonance imaging (MRI); 2) left ventricular mass index as assessed by MRI; 3) urinary albumin excretion; and 4) endothelial-dependent vasodilation as assessed by brachial ultrasound. A total of 110 subjects were enrolled in this research study. This study involved pediatric subjects because the Investigators believe that early intervention is critical if they are to decrease the morbidity and mortality associated with this condition. If pravastatin is shown to be effective in ameliorating progression of renal and cardiovascular disease in this study, routine management of people with this condition will be drastically altered. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00456365
Study type Interventional
Source University of Colorado, Denver
Contact
Status Completed
Phase Phase 3
Start date November 2006
Completion date October 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Completed NCT04363554 - The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05521191 - A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 1
Completed NCT03687554 - Effect of Venglustat in Patients With Renal Impairment Phase 1
Terminated NCT03523728 - A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Phase 2/Phase 3
Completed NCT00565097 - Lanreotide as Treatment of Polycystic Livers Phase 2/Phase 3
Completed NCT00410007 - The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02251275 - Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT01559363 - A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease Phase 1/Phase 2
Completed NCT02903511 - Feasibility Study of Metformin Therapy in ADPKD Phase 2
Recruiting NCT05510115 - Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT02494141 - Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD Phase 4
Completed NCT04407481 - PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
Completed NCT02847624 - Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
Completed NCT03342742 - Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT02656017 - Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Phase 2
Completed NCT04023214 - The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
Terminated NCT01589705 - The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease N/A
Completed NCT00426153 - Octreotide in Severe Polycystic Liver Disease Phase 2/Phase 3
Completed NCT04534985 - Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease N/A